EDAP TMS S.A. Reports $70.5 Million Revenue with Focus on HIFU Technology

EDAP TMS S.A. reported a total revenue of $70.5 million for the fiscal year ending December 31, 2025, marking a 1.6% increase from $69.4 million in 2024. The company's HIFU division saw significant growth, with revenues rising 44.8% to $37.4 million, driven by a 72.1% increase in medical device sales, which totaled $18.1 million. This included the sale of 35 Focal One units, compared to 22 units sold in the previous year. In contrast, the ESWL division experienced a decline in revenue, dropping 23.2% to $7.5 million, while the Distribution division's revenues fell 24.1% to $25.7 million, primarily due to the termination of distribution agreements.

The company's gross profit increased to $30 million, representing a gross margin of 42.5%, up from 41.4% in 2024. This improvement was attributed to higher sales volumes in the HIFU division, which typically yields higher margins. However, EDAP TMS reported a net loss of $29.2 million for 2025, compared to a loss of $20.6 million in 2024. The increase in losses was influenced by rising operating expenses, which grew by 7.3% to $54.7 million, driven by higher research and development costs associated with HIFU programs.

Strategically, EDAP TMS has shifted its focus to its HIFU technology, discontinuing new system sales in its ESWL division and reducing emphasis on its Distribution activities. This realignment is expected to enhance long-term growth prospects, particularly as the company seeks to expand its HIFU applications beyond prostate cancer to include conditions like benign prostatic hyperplasia and endometriosis. The company is also pursuing clinical studies to support these expanded indications.

Operationally, EDAP TMS employed 289 individuals as of December 31, 2025, with approximately 24% based in the United States. The company has made significant investments in research and development, with expenses rising to $9.7 million, reflecting its commitment to advancing its HIFU technology. Additionally, the company plans to draw €12 million from a credit facility with the European Investment Bank in April 2026, which it believes will support its operations for at least the next twelve months.

Looking ahead, EDAP TMS anticipates continued challenges due to market conditions, including inflation and competition in the medical device sector. The company is focused on enhancing its product offerings and expanding its market presence, particularly in the U.S. and Europe, while navigating the complexities of regulatory approvals and reimbursement landscapes.